Acarix
0,257 SEK -0,58%Vær den første som følger denne virksomhed
Acarix is a diagnostics company. The company has developed a technology that enables the identification of coronary heart disease. The company's product is a non-invasive test that is put with a note on the patient to analyze sound from the heart. Operations are mainly conducted in the Nordic market. The company was founded in 2009 as a spin-off from Coloplast. The head office is located in Malmö.
Omsætning
6,24 mio.
EBIT %
-1.242,79 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
ACARIX
Daglig lav / høj pris
0,25 / 0,26
SEK
Markedsværdi
235,52 mio. SEK
Aktieomsætning
476,47 t SEK
Volumen
1,9 mio.
Finanskalender
Generalforsamling
14.05.2024
Delårsrapport
14.05.2024
Delårsrapport
22.08.2024
Delårsrapport
07.11.2024
Årsrapport
13.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Försäkringsaktiebolaget, Avanza Pension | 8,4 % | 8,4 % |
Mikael Thorén | 4,2 % | 4,2 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Acarix receives declarations of intent to exercise warrants of series TO 2
CEO purchases shares in Acarix
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools